Jin Matrix Receives US FDA Emergency Use Authorization for COVID-19 Diagnostic Kit

[Asia Economy Reporter Minji Lee] Jin Matrix's 'Neoplex COVID-19' has obtained Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA), the company announced on the 15th.

Jin Matrix stated that it received the EUA certificate for 'Neoplex COVID-19' issued by the U.S. FDA on the 14th (local time).

'Neoplex COVID-19' is a product designed according to the standards of the U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO). It features the ability to perform batch testing with a single tube, enabling rapid and efficient analysis of large volumes of specimens.

The company expects this opportunity to make Jin Matrix's entry into the U.S. market more tangible. The kit is a universal kit compatible with various equipment and systems and will be supplied without restrictions to multiple medical institutions across the U.S.

Currently, the 'Neoplex COVID-19' kit is supplied to Europe, South America, the Middle East, and North America. With the FDA's EUA in the U.S., export expansion is anticipated not only in the U.S. but also across the global market.

A Jin Matrix representative said, "We have already signed contracts with companies located in the region to ensure rapid entry into the U.S. market," adding, "We are also solidifying company-wide preparations to supply large quantities to global markets including Europe, South America, and the U.S."

This content was produced with the assistance of AI translation services.